# A Multicenter, Study of the Safety and Pharmacokinetics of Intravenously Infused Berubicin in Pediatric Patients With Progressive, Refractory, or Recurrent High Grade Gliomas

> **NCT05082493** · PHASE1 · WITHDRAWN · sponsor: **WPD Pharmaceuticals Sp. z o.o.**

## Conditions studied

- High Grade Glioma

## Interventions

- **DRUG:** Berubicin Hydrochloride

## Key facts

- **NCT ID:** NCT05082493
- **Lead sponsor:** WPD Pharmaceuticals Sp. z o.o.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-12
- **Primary completion:** 2023-12-30
- **Final completion:** 2023-12-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Business decision
- **Last updated:** 2024-06-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05082493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05082493, "A Multicenter, Study of the Safety and Pharmacokinetics of Intravenously Infused Berubicin in Pediatric Patients With Progressive, Refractory, or Recurrent High Grade Gliomas". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT05082493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*